Drs Harrington and Gibson's annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ever lower LDL-C with drugs or even gene editing are among the highlights.

This podcast is intended for healthcare professionals only.

To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington

New ACS Guidelines

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes

https://doi.org/10.1161/CIR.0000000000001309

ACS Guideline Chair and Vice-Chair Discussion

https://www.medscape.com/viewarticle/acs-guidelines-2025-key-points-chair-and-vice-chair-2025a100093l

Antiplatelet/Antithrombotic Strategies

Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI

https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt

Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET)

https://www.nejm.org/doi/full/10.1056/NEJMoa2507980

Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC)

https://www.nejm.org/doi/full/10.1056/NEJMoa2507532

Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making : ENGAGE AF-TIMI 48 Trial Analysis

https://doi.org/10.1016/j.jacadv.2025.102504

Factor XI Inhibitors

Bristol Myers, J&J Stop Blood Clotting Drug Trial After Interim Review

https://www.medscape.com/s/viewarticle/bristol-myers-j-j-stop-blood-clotting-drug-trial-after-2025a1000vqu

Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention https://www.bayer.com/en/us/news-stories/oceanic-stroke

OAC-Naive Subgroup From OCEANIC-AF Published

https://www.medscape.com/viewarticle/novel-blood-thinner-shows-promise-atrial-fibrillation-2025a10008lz

GLP-1 and Myotrophic Drugs

Lilly's Next-gen Drug Shows Greater Weight Loss Than Zepbound in Late-stage Trial (TRIUMPH-4)

https://www.medscape.com/s/viewarticle/lillys-next-gen-drug-tops-zepbound-weight-loss-late-stage-2025a1000ys1

Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial

https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf

CRISPR and Lipid Lowering

Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease

https://www.nejm.org/doi/full/10.1056/NEJMoa2504747

Gene Therapy Shows Lipid Improvement but Raises Flags

https://www.medscape.com/viewarticle/gene-therapy-shows-lipid-improvement-raises-flags-2025a1000uzw

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3

https://www.nejm.org/doi/full/10.1056/NEJMoa2511778

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (VESALIUS-CV)

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2514428

Prehospital GLP IIb/IIIa

Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction (CELEBRATE) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268

You may also like:

Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology

https://www.medscape.com/twic

Questions or feedback, please contact news@medscape.net

Drs Harrington, Rodriguez, and Ridker discuss the changing field of cardiac prevention, where imaging fits in, and the new concept of standard modifiable risk factor-less patients.

This podcast is intended for healthcare professionals only.

To read a transcript or to comment, visit

https://www.medscape.com/author/bob-harrington

Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association

https://doi.org/10.1161/CIR.0000000000001078

Development and Validation of the American Heart Association's PREVENT Equations

https://doi.org/10.1161/CIRCULATIONAHA.123.067626

C-Reactive Protein and Cardiovascular Risk Among Women With No Standard Modifiable Risk Factors: Evaluating the 'Smurf-Less but Inflamed'

https://doi.org/10.1093/eurheartj/ehaf658

Mortality in STEMI Patients Without Standard Modifiable Risk Factors: A Sex-Disaggregated Analysis of SWEDEHEART Registry Data

https://doi.org/10.1016/S0140-6736(21)00272-5

Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women

https://www.nejm.org/doi/10.1056/NEJMoa2405182

Statins for the 'SMuRFLess But Inflamed': Silent Vascular Inflammation and the Challenge of Translational Science

https://doi.org/10.1016/j.jacbts.2025.101318

VERVE-101: A Promising CRISPR-Based Gene Editing Therapy That Reduces LDL-C and PCSK9 Levels in HeFH Patients

https://academic.oup.com/ehjcvp/article/10/2/89/7492807

You may also like:

Hear John Mandrola, MD, give a summary and his perspective on the top cardiology news each week, on This Week in Cardiology

https://www.medscape.com/twic

Questions or feedback, please contact news@medscape.net

Cardiologist and author Eric Topol discusses the science of longevity, why the key to healthy aging is prevention, and the perils of a fixation on reversing ageing.

This podcast is intended for healthcare professionals only.

To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington

Super Agers: An Evidence-Based Approach to Longevity

https://www.simonandschuster.com/books/Super-Agers/Eric-Topol/9781668067666

Wellderly study

https://www.scripps.edu/science-and-medicine/translational-institute/translational-research/genomic-medicine/wellderly/

Lotte Bjerre Knudsen

https://erictopol.substack.com/p/lotte-bjerre-knudsen-the-scientist

Organ aging signatures in the plasma proteome track health and disease

https://doi.org/10.1038/s41586-023-

Deep Medicine

https://drerictopol.com/portfolio/deep-medicine/

You may also like:

Hear John Mandrola, MD, give a summary and his perspective on the top cardiology news each week, on This Week in Cardiology

https://www.medscape.com/twic

Questions or feedback, please contact news@medscape.net